[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509102":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":33,"locations":43,"responsibleParty":73,"collaborators":75,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":29,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":29,"enrollmentInfo":87,"targetDuration":29,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":29,"overallStatus":46,"whyStopped":29,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Northside Hospital, Inc.","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Moderate Renal Dysfunction","EXPERIMENTAL","Moderate renal dysfunction will receive a 20% dose reduction of fludarabine and no dose reduction for cyclophosphamide.",[13,14],"Drug: Fludarabine","Drug: Cyclophosphamide",{"label":16,"type":10,"description":17,"interventionNames":18},"Severe Renal Dysfunction","Several renal dysfunction will receive a 40% dose reduction of fludarabine and no dose reduction for cyclophosphamide.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Dialysis Participants","Participants on dialysis will receive a 50% dose reduction of fludarabine and a 25% dose reduction of cyclophosphamide.",[13,14],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Fludarabine","Received IV on Days -5 to -3 before CAR T cell therapy",[20,9,16],null,{"type":25,"name":31,"description":27,"armGroupLabels":32,"otherNames":29},"Cyclophosphamide",[20,9,16],[34,39],{"name":35,"role":36,"phone":37,"phoneExt":29,"email":38},"Melhem Solh, MD","CONTACT","404-255-1930","msolh@bmtga.com",{"name":40,"role":36,"phone":41,"phoneExt":29,"email":42},"Caitlin Guzowski, MBA, MHA","404-851-8523","caitlin.guzowski@northside.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Caitlin Guzowski","RECRUITING","Atlanta","Georgia","30342","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-84.38798,33.749,{"lat":56,"lon":55},[59,60,63,65,67,69,71],{"name":40,"role":36,"phone":41,"phoneExt":29,"email":42},{"name":61,"role":62,"phone":29,"phoneExt":29,"email":29},"H. Kent Holland, MD","SUB_INVESTIGATOR",{"name":64,"role":62,"phone":29,"phoneExt":29,"email":29},"Asad Bashey, MD",{"name":66,"role":62,"phone":29,"phoneExt":29,"email":29},"Lawrence E Morris, MD",{"name":68,"role":62,"phone":29,"phoneExt":29,"email":29},"Scott Solomon, MD",{"name":35,"role":70,"phone":29,"phoneExt":29,"email":29},"PRINCIPAL_INVESTIGATOR",{"name":72,"role":62,"phone":29,"phoneExt":29,"email":29},"Lizamarie Bachier-Rodriguez, MD",{"type":74,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[76],{"name":77,"class":6},"Blood and Marrow Transplant Group of Georgia","100509102","phase-2-car-t-cell-therapy-in-patients-with-renal-dysfunction-100509102",false,"NCT05909059","CAR T-cell Therapy in Patients With Renal Dysfunction","Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction","Inclusion Criteria:\n\n* Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma\n* Adequate bone marrow function to receive lymphodepleting chemotherapy\n* Renal function \\\u003C\u002F= 60mL\u002Fmin\u002F1.73m2\n* ECOG 0-2\n\nExclusion Criteria:\n\n* Relative CNS disorders\n* Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator\n* Use of therapeutic dose systemic corticosteroids (defined as \\>20mg\u002Fday prednisone or equivalent) within 72 hours of CAR-T administration","ALL","18 Years",{"count":88,"type":89},20,"ESTIMATED","INTERVENTIONAL",[92],"PHASE2","This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.",[95,96,97],"Non-hodgkin Lymphoma,B Cell","Multiple Myeloma","Acute Lymphoblastic Leukemia, Adult","2026-04-15",{"date":100,"type":101},"2026-04-20","ACTUAL",{"date":103,"type":101},"2024-11-18",{"date":105,"type":89},"2027-08-31",{"name":5,"class":6},1]